---
title: "Playbook — How to Manufacture Orthopedic Implants Using Maximal Automation"
type: output
subtype: playbook
created: 2026-07-22
question: "How to manufacture orthopedic implants using maximal automation?"
tags: [playbook, orthopedic-implants, automation, manufacturing, additive, machining, regulatory]
confidence: high
sources: 26
---

# How to Manufacture Orthopedic Implants Using Maximal Automation

**The question:** How do you manufacture orthopedic implants (hips, knees, spine, trauma,
extremities) using maximal automation — and where are the real limits?

**The short answer:** Sequence the build into stations and automate each to a different degree.
The **material's thermal conductivity + hardness/reactivity** dictates the forming route; the
**obligation to validate** (not robotics) sets the ceiling. The machining core already runs
24/7 lights-out with closed-loop CMM→CNC correction. The recent breakthrough is **automated
finishing** that kills the hand-polish bottleneck. The remaining gaps are the **AM post-
processing tail**, **black-box AI inspection**, and the **human sign-off on the Device History
Record**. Because ortho is high-mix/low-volume, the right architecture is **flexible robotic
cells + cobot tending + single-piece flow**, not hard automation — and you **buy** the hard
stations rather than build them.

> This is the standalone, shareable deliverable. The living version with full cross-links is
> the [Build Playbook](../reference/build-playbook.md); the reasoning lives in the
> [concept articles](../_index.md).

---

## Key findings, by sub-question

**1. What is the process chain?** Design → material → forming (CNC/Swiss/AM/forge/cast) → AM
post-processing → finishing → coating → clean → passivate/anodize → inspect → laser-mark (UDI)
→ package → sterilize → release. Automation is decided *per station*; they differ enormously.

**2. What are the forming routes, and which is most automatable?** Subtractive dominates:
**Swiss-type lathes make ~95% of bone screws** (bar-fed lights-out) and 5-axis machining owns
hips/knees. **Metal AM** (L-PBF vs EBM) owns porous, bone-mimicking geometry — and is now
serial (AddUp: **21,735 hip cups/yr/machine at 78% OEE**; Stryker Tritanium: **300k+ devices in
10 years**). Forging aligns grain for fatigue; investment casting feeds CoCr heads.

**3. How does material dictate everything?** Low thermal conductivity → heat at the cutting edge
→ tool wear (titanium, 6.7 W/m·K, 80% heat into edge). High hardness → grind/polish not turn
(CoCr >50 HRC). High melting point/reactivity → exotic forming (tantalum CVD at 2980 °C mp,
ceramic sinter+grind). Titanium is *miserable to machine but ideal to print* — which is why
titanium implants push to AM.

**4. Can polishing be automated?** Yes — this is the biggest recent win. **DLyte dry
electropolishing** finished **24 CoCr knee components to Ra < 0.05 µm in 60 minutes**; Rösler
drag, OTEC stream, and PushCorp/Acme force-control robots complete the toolkit. Acme alone has
**>150 robotic finishing systems installed for orthopedics.** The historic hand-polish
bottleneck is falling.

**5. How is inspection automated?** Cobot-loaded CMM (Zeiss ShuttleLoad/MultiLoad) runs
unmanned overnight; **industrial CT is the only NDT for AM internal porosity**; optical GD&T and
AI cosmetic vision run in-line. **Closed-loop CMM→CNC feedback** is the mechanism that makes a
*regulated* line run lights-out. AI vision uses **two-tier human escalation** because black-box
models can't be fully validated. Implants trend to **100% inspection / c=0**.

**6. What actually bounds automation?** **Validation, not robotics.** 21 CFR 820.75: any process
whose output isn't fully inspectable must be *validated with high assurance* → IQ/OQ/PQ on every
cell. 820.70(i) adds software validation. **FDA CSA** (risk-based) is the lever making this
affordable. QMSR (ISO 13485 harmonization) is effective **Feb 2, 2026**.

**7. What are the economics?** Ortho is **high-mix/low-volume** → flexible robotic cells + cobot
tending + single-piece flow beat hard automation. ROI comes from **repeatability + capacity +
labor**, not speed. The [lights-out cell](../raw/repos/2026-07-22-flexxbotics-mach-medical-lights-out-cell.md)
delivered **+61% capacity, +44% throughput, 20:1 machine-to-labor, 3-week (from 20) lead time,
scrap <1%, lot size one.** Market: **$7B→$15.3B (8.8% CAGR)**; Tecomet+Orchid merged May 2026.

**8. What still isn't automated?** The **AM post-processing tail** (~20 hr/part L-PBF:
depowdering, support removal, HIP), **ceramic finishing** (defects = crack initiators),
**black-box AI accept/reject**, and the **human DHR sign-off**.

---

## The actionable playbook

### Decision 0 — Should you automate, and how much?
Ortho is HMLV. High-runner SKUs (screws, common cups) → dedicated Swiss lines / AM fleets. The
variant tail → flexible cells or semi-manual. Justify capital on repeatability + capacity +
labor, not peak speed. Default architecture: **flexible robotic cells + cobot tending +
single-piece flow.**

### Decision 1 — Material → route (do FIRST)
- Bone screws / trauma (316L, Ti) → **Swiss lathe**, lights-out.
- Hip stems / femoral components (load-bearing) → **forge → 5-axis**.
- Femoral heads (CoCr / ceramic) → cast/wrought → 5-axis + **heavy finishing** / sinter+grind.
- Porous cups, cages, patient-specific (Ti) → **metal AM** (EBM bulk, L-PBF fine).
- Bearing liners (UHMWPE) → machine → gamma-crosslink → **vitamin-E** → inert sterilize.

### Decision 2 — Design validation in from day one
Assume 820.75 applies → IQ/OQ/PQ each cell; validate automation software (820.70(i)) and
**scope it with CSA**; born-digital DHR + Part 11 audit trails; UDI mark placement that doesn't
compromise the fatigue surface; prefer high-Cpk processes; mind QMSR (Feb 2, 2026).

### Build order (mature/cheap first, bottlenecks last)
1. Design/CAD-CAM (validated SW).
2. Forming — machining core runs **lights-out** (5-axis + in-line CMM + wash, one robot,
   closed-loop).
3. AM post-processing (semi-auto bottleneck): depowder → support removal → **HIP** → heat treat
   → finish-machine.
4. **Finishing — automate the polish** (DLyte / drag / stream / force-control). Highest payoff.
5. Coating — 6-axis robot HA plasma spray (>62% crystallinity), or print integral AM porosity.
6. Clean (automated ultrasonic; verify ISO 19227).
7. Passivate/anodize (F86/A967; Type II AMS 2488).
8. Inspect — cobot CMM, **CT for AM internals**, optical GD&T, AI vision + human escalation;
   100%/c=0.
9. Mark — UDI laser (fatigue-safe).
10. Package — HFFS to ISO 11607.
11. Sterilize — gamma / EtO / e-beam / steam (usually outsourced).
12. Release — validated **human sign-off** on the DHR.

### Buy vs. build
**Buy the hard stations, integrate the cell.** Machining: DMG MORI / Willemin / Tornos / Star /
Citizen / Matsuura. Orchestration: **Flexxbotics** + Universal Robots / FANUC. Finishing:
**Acme** / AV&R / PushCorp + DLyte / Rösler / OTEC. AM: EOS / GE-Arcam / AddUp / Renishaw.
Metrology: Zeiss + VisionGauge. Or outsource to a scaled CMO (**Tecomet/Orchid**, Paragon,
Viant).

---

## Worked examples (proof it's real)

- **Lights-out machining cell (Flexxbotics + Mach Medical):** Okuma 5-axis + Universal Robots
  cobot + in-line CMM + wash, single robot, 24/7, closed-loop CMM→CNC. +61% capacity, scrap
  <1%, lot size one, per-implant DHF traceability. *The proof that the machining core can run
  lights-out for a regulated implant.*
- **Serial metal AM (AddUp / Stryker / Lima / Orchid):** AddUp FormUp 350 = 21,735 hip
  cups/yr/machine at 78% OEE; Stryker Tritanium 300k+ devices/10 yr; Lima/Enovis 15 EBM
  machines; Orchid stackable Spectra L. *Proof that AM porous parts are a serial-production
  reality.*
- **Automated finishing (DLyte / Acme):** 24 CoCr knees to Ra < 0.05 µm in 60 min; Acme 150+
  ortho robotic finishing installs. *Proof the hand-polish bottleneck is falling.*

---

## Derived theses (candidates for `--mode thesis`)

1. **"The binding constraint on orthopedic manufacturing automation is regulatory validation
   burden, not robotic capability."** — Testable against cases where robotics exist but aren't
   deployed due to validation cost, and where CSA adoption unlocked automation.
2. **"Automated finishing (electropolishing / mass finishing / force-control robotics) has
   eliminated manual polishing as the dominant labor bottleneck in CoCr implant production."** —
   Testable against per-part labor-hour data before/after automated finishing adoption.
3. **"Metal additive manufacturing's post-processing tail — not printing throughput — is the
   deciding cost/automation constraint for serial AM orthopedic implants."** — Testable against
   cost breakdowns (print vs. depowder/HIP/machine) and OEE attribution.

---

## Sources

26 ingested sources (5 papers, 4 articles, 3 case/vendor references, 14 regulatory/technical
data notes). See the [raw index](../raw/_index.md). Highest-confidence anchors:

- Lights-out cell (triangulated by 3 agents): Today's Medical Developments; Modern Machine Shop.
- Serial AM cases: Additive Manufacturing Media; Engineering.com; AddUp.
- Regulatory: 21 CFR 820.75 / 820.70(i) / Part 11 / 801.45; FDA CSA guidance; QMSR.
- Materials/machinability: titanium tool-wear, CoCrMo, PEEK/SS machinability data notes.
- Finishing: DLyte / Rösler / OTEC / PushCorp; Acme / AV&R vendor data.

*Skipped (access-blocked): several ScienceDirect / MDPI / Orthopedic Design & Technology URLs
(403). Findings triangulated from open sources instead.*

